Medicine
Fragmin 10000 IU/mL injection
Fragmin 10000 IU/mL injection is a prescription medicine containing Dalteparin for subcutaneous use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursion permitted between 15°C to 30°C…
Key facts
- Active ingredient (INN)
- Dalteparin
- Brand
- Fragmin
- Strength
- 10000 IU/mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 10 syringes
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturer
- Pfizer Laboratories
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursion permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- B01AB04 Dalteparin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 April 2015
- Identifiers
- RxCUI 978725, 978727, 978733 +7DailyMed set ID 23527b8b-9b28-4e6d-9751-33b143975ac7NDC 0069-0217Application NDA020287
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 syringe in 1 carton / 1 mL in 1 syringe | 0069-0217-02 | Pfizer Laboratories | 1 April 2015 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 22 December 1994 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Dalteparin
Clinical summary
Dalteparin is an anti-coagulant indicated for prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, among other approved uses. It is available as injection for subcutaneous use. MedsAcross supplies Dalteparin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DalteparinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Fragmin prescribing information (Pfizer Laboratories) · U.S. National Library of Medicine, DailyMed
Need Fragmin 10000 IU/mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.